Ferric Polymaltose Complex (Ferose) in Treatment of Iron Deficiency and Iron Deficiency Anemia with Pregnancy
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 122
研究概览
简要总结
Results: The pre-treatment ferritin, and hemoglobin significantly increased, 3-months after ferric polymaltose (FPM (Ferose®)) treatment. In addition, the mean pre-treatment red-blood cells volume and red-blood cells hemoglobin significantly increased 3-months after ferric polymaltose (FPM (Ferose®)) treatment. Conclusion. The ferric polymaltose (Ferose®) is an effective therapeutic option for treatment of iron deficiency and iron deficiency anemia during pregnancy with high safety profile, and low side effects. The superior tolerability of ferric polymaltose is an important advantage because compliance to oral iron is the main obstacle toward effective treatment of iron deficiency and iron deficiency anemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 20 Years 至 40 Years(—)
- 性别
- Female
入选标准
- •Inclusion criteria include; pregnant women equal or more than 20 years old, 14-26 weeks` gestation with serum ferritin less than 15 ug/l and hemoglobin less than or equal 10 gm/dl.
排除标准
- •Exclusion criteria include; pregnant women with intolerance or hypersensitivity to oral iron and/or anemia other than iron deficiency anemia and/or received blood transfusion during current pregnancy.
